Implementing Changes in Pharmacovigilance Regulations. Presented by Dr Ennis H Lee, Senior Partner, TranScrip 14 June 2016

Similar documents
Guidance notes for patient safety and pharmacovigilance in patient support programmes

Safeguarding public health. The New PV Legislation. Perspective from a Member State

Corporate Induction: Part 2

The New EU PV Legislation: View from the European Commission

TRAINING CALENDAR 2018

Pharmacovigilance documents in the life cycle of a medicinal product: DSUR, RMP, PSUR/PBRER, and Addendum to the Clinical Overview

BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS

Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective

Capturing the value of SCOPE to the EU Flagship Event London, 23 November 2016

Safeguarding public health. The New PV Legislation its Impact on PV & MI

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE

Good Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA

New Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA)

Pharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist

Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013

WHO Pharmacovigilance Indicators. Dr. Nitin Gaikwad Co-coordinator, ADR Monitoring Center, PvPI Additional Professor, Pharmacology AIIMS Raipur

Continuous Professional Development of Health Professionals European Context

GCP INSPECTORATE GCP INSPECTIONS METRICS REPORT

Pharmacovigilance Training

WHO Programme for International Drug Monitoring, Pharmacovigilance Centres & Patient Safety

Teleconference Course Materials You may duplicate this for each person attending the conference.

1. PURPOSE 2. SCOPE 3. RESPONSIBILITIES

Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes

Measures of impact of pharmacovigilance processes (3.3)

ZAMBIA MEDICINES REGULATORY AUTHORITY EMPLOYMENT OPPORTUNITY

MedDRA Coding and Medication Error Topics. Patrick Revelle (MSSO)

Overview of Draft Pharmacovigilance Protocol

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA

District of Columbia Prescription Drug Monitoring Program

Sponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Changing Requirements for Devices//Device Constituent Parts in Combination Products

Marie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager

Quality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D

INVOLVING PATIENTS IN PHARMACOVIGILANCE EPF TOOLKIT. Susanna Palkonen, EPF Board Member

Pharmacovigilance in Kenya

Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission

NATIONAL ASSOCIATION FOR STATE CONTROLLED SUBSTANCES AUTHORITIES (NASCSA) MODEL PRESCRIPTION MONITORING PROGRAM (PMP) ACT (2016) COMMENT

Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine

What does governance look like in homecare?

Issue 7/ Jul - Sept 2012

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

Safety Reporting in Clinical Research Policy Final Version 4.0

Do you suffer from diabetes? Do you want to shape the future of diabetes care?

Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

Pharmacovigilance in Middle East Conference

The National Patient Experience Survey Programme. Statement of information practices

New European Union Clinical Trial Regulations

Pharmacovigilance Office of Product Review

2012 Medicare Compliance Plan

Guidance for MRC units on HTA licence applications for storage of human samples for research purposes

SCOPE Work Package 4 ADR Collection. Medication Errors

Compliance Program Updated August 2017

Clinical Research Professionals

Cleaning Manual. Fitzroy Falls aged Care Facility. J.N. Bailey 2009 Fitzroy Falls Aged Care Facility - Cleaning Manual Version 1.0.

MedDRA User Group. Paris, April 16, 2015 Victoria Newbould, European Medicines Agency. An agency of the European Union

SCOPE Work Package 4 ADR Collection. Handling Telephone Calls from the Public

Patient Centricity In Pharmacovigilance:

Strengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) Joint Action

LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS

Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1

Performance, Innovation, and Improvement Grant Application

High level guidance to support a shared view of quality in general practice

Provided below is the background, discussion, and recommendations from the panelists.

REQUEST FOR PROPOSAL (RFP)

General information. Name: Colin Sainsbury

Homecare Medicines Charter

WHO role in the introduction of new TB drugs and regimens: (2) Supporting introduction in countries

The Strategic Content Alliance. Sustaining Digital Resources

IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES

Improving the Safety of International Non-proprietary Names of Medicines (INNs) Position Statement 2011

Standard Operating Procedure

Current Status: Active PolicyStat ID: Origination: 09/2004 Last Approved: 02/2017 Last Revised: 09/2013 Next Review: 02/2019

Administrative services which may be delegated to IPAs, Medical Groups, Vendors, or other organizations include:

Required Activities (continued)

R. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager

POST-LAUNCH DEMANDS: Dr Thomas Lönngren ISPOR Content

Self-assessment worksheet for the Professional Practice Standards version 4

Baltimore-Towson EMA Part A Quality Management (QM) Plan I. Introduction

Proposed amendments to the Marihuana for Medical Purposes Regulations

Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland

SKAC240 Manage health, safety, security and welfare in sport and active leisure

HUMAN RESOURCES POLICY

SOP Title: Reporting Adverse Events and New Safety Information

3 HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION

European Patients Academy (EUPATI) Update

SFHPHARM11 - SQA Unit Code FA2X 04 Prepare extemporaneous medicines for individual use

HEALOGICS, INC. ~ VENDOR CODE OF CONDUCT

Role Profile Medical Officer- Medical Devices

Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Table 1. Big Data Sources of Interest for Pharmacovigilance (PV)

Finance. Date to Committee: March 26, 2013 Date to Council: April 8, 2013

Report of an inspection of a Designated Centre for Disabilities (Children)

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018

CPD Cycle from 1 January 2013/2014/2015 to 31 December 2013/2014/2015. Notes. Solicitor s Name:

Information Brochure Professional Certificate in Pharmacovigilance

Managing medicines in care homes

Details: Approval: Distribution & Storage: Pharmacovigilance for Researchers for UoL / LTHT Sponsored CTIMPs. Standard Operating Procedure

Transcription:

s Presented by Dr Ennis H Lee, Senior Partner, TranScrip 14 June 2016

Monitor for changes in regulations Regulatory Authority websites Pharmaceutical industry bodies Pharmaceutical press Use global subsidiaries An Indegene and TranScrip alliance Private & Confidential 2

Get involved in shaping new regulation Review legislation and guidance documents Comment directly to Regulatory Authorities Comment via industry bodies Attend Regulatory Authority briefing meetings An Indegene and TranScrip alliance Private & Confidential 3

Communicate change Up - Senior Management Down Staff / Contractors Sideways Global subsidiaries Licence partners Vendors An Indegene and TranScrip alliance Private & Confidential 4

Updating of EU PV Legislation Extensive changes to EU PV regulation started with legislation implementation in 2012 Major changes to the requirements for a company PV System were needed Change is still ongoing and will be for some time IT systems to support PV still not operational Resource is a major challenge for all An Indegene and TranScrip alliance Private & Confidential 5

Challenges of the EU legislation change Change in the definition of ADR Requirements to collect AEs medication errors, overdose, abuse, etc. New signal management needs New format safety documents DSUR, EU-RMP, etc. Pharmacovigilance System Master File Requirements for global safety data, documenting global PV vendors, Partner agreements, etc. Audit requirements and documentation An Indegene and TranScrip alliance Private & Confidential 6

Global PV System One global assessment of drug safety Global standards, labelling, etc Data from global company sources Global company databases Actions in one country affect all other countries Document pharmacovigilance practice and standards An Indegene and TranScrip alliance Private & Confidential 7

Task Forces Get buy-in from and set up feedback mechanism to senior management Appoint an influential chair and a lead for each function Charter of goals and activities Manage an action list and costings Site for all documentation Feedback from all functions on how changes will influence their practice, if at all Expect challenges! An Indegene and TranScrip alliance Private & Confidential 8

Assess change needed Assess regulatory and guidance documents one function leading: Assess changes needed Consider impact on other countries Will IT systems help? Knock-on effects to Partners, Vendors, etc Allocate actions for each function An Indegene and TranScrip alliance Private & Confidential 9

Make an implementation plan What needs to change What When By whom Transition plan Communication plan Costings for change Feedback for senior management An Indegene and TranScrip alliance Private & Confidential 10

Controlled documents Review all current controlled document for changes Appoint a lead for all updates and new documents Set timelines Mechanism to roll-out to relevant staff groups Assess compliance with training real-time Set criteria to measure effectiveness and measure An Indegene and TranScrip alliance Private & Confidential 11

Training and roll-out Communication plan Explain need and how change will be managed Assess training needs globally by function Set challenging but realistic goals Management oversight of compliance Set Goals and Objectives for staff globally Ongoing CPD requirements An Indegene and TranScrip alliance Private & Confidential 12

Implementation Set dates for changes Regularly assess progress against the plan Document change and inform Regulatory Authorities of changes as required Regularly feedback Senior management (reports) Staff globally (newsletters) Minimise confusion! An Indegene and TranScrip alliance Private & Confidential 13

Audit, review and update Internal audit plan to review new processes and practices as part of implementation Audit by both process and function Regularly feedback to senior management Manage a CAPA process to ensure compliance with required changes Update processes and repeat the cycle of change management and audit An Indegene and TranScrip alliance Private & Confidential 14

The challenges of Pharmacovigilance! An Indegene and TranScrip alliance Private & Confidential 15